Fraunhofer-Institut für Toxikologie und Experimentelle Medizin

BIO-Europe 2023

Partneringkonferenz der Biotechnologiebranche / 06. November 2023 - 08. November 2023

BIO-Europe – internationales Branchentreffen

Vom 6. bis 8. November 2023 findet das internationale Branchentreffen BIO-Europe® in München statt. Besuchen Sie Vertreterinnen und Vertreter der Fraunhofer-Gesundheitsforschung am Gemeinschaftsstand »Fraunhofer Gesundheit«.

Veranstaltungsdetails

Programm

Weitere Informationen zur BIO-Europe 2023 finden Sie auf der Konferenz-Website

Veranstaltungsort

München

Datum

06. November 2023 - 08. November 2023

Dies sind unsere Themen auf der BIO-Europe 2023

Personalized Tumor Therapy

The division for Personalized Tumor Therapy has a clear focus on driving research on personalized cancer diagnostic and preclinical drug development in patient-derived models.

We are happy to support you as a reliable partner in the following areas:

For preclinical drug development, we have recently developed a Platform for Ex-Vivo Drug Response Assays (PEDRA). PEDRA can reflect the clinical patient situation in vitro by making use of disease specific models, being generated from clinical samples individually recruited for each project.

Our services

Inhalation Toxicology

We are committed to provide customized solutions for aerosolization and testing of drug candidates including small molecules, recombinant proteins, cell and gene therapies or bacteriophages.

We are happy to support you as a reliable partner with our key expertise in:

Inhaled administration and (GLP-certified) toxicity assessment
Toxicokinetics of inhaled particles
Formulation analytics

With our inhouse-knowledge of histopathology, hematology and clinical chemistry, as well as our portfolio in safety pharmacology testing, we provide full preclinical service for translation to clinical phase trials.

Our services

Infection Research and Immunology

We provide disease-relevant, dose-dependent, and reproducible models ranging from patented in-vitro to complex ex-vivo and in-vivo solutions. As such, we are happy to test the efficacy of your lead compound:

Fully immune-competent, all-human ex-vivo models for respiratory viruses, i.e. rhinovirus, RSV, influenza, parainfluenza and SARS-CoV-2
In-vivo models in mouse and cotton rat
Bacterial infection and biofilm models, e.g. Pseudomonas aeruginosa

This expertise is complemented by close in-house interactions with our inhalation experts, enabling efficient nebulization of compounds.

Our expertise

PEDRA: Platform for Ex-Vivo Drug Response Assays

Interested in knowing how PEDRA can help you to improve the successful clinical translation of your drug candidates?

Feel free to send a request via partneringONE® and our experts will be pleased to meet you at the Bio-Europe 2023 in person.

Treffen Sie uns auf der BIO-Europe 2023!

Kontaktieren Sie uns gerne und wir vereinbaren ein Termin!

Contact Press / Media

Dr. Christopher Jakobs

Business Development Personalisierte Tumortherapie

Telefon +49 152 28220636

E-Mail senden
christopher.jakobs@item.fraunhofer.de
Zum LinkedIn-Profil

Contact Press / Media

Dr. Sebastian Konzok

Business Development Präklinische Pharmakologie, Chemikaliensicherheit und Toxikologie

Telefon +49 172 410 7965

E-Mail senden
sebastian.konzok@item.fraunhofer.de

Contact Press / Media

Prof. Dr. Armin Braun

Bereichsleiter Präklinische Pharmakologie und Toxikologie

Telefon +49 511 5350-263

E-Mail senden
armin.braun@item.fraunhofer.de
Zum LinkedIn-Profil